99.15
+7.48%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Morepen Laboratories
Its shares trade on NSE under the ticker MOREPENLAB.NS. It has been listed since 16 November 1992. In the fiscal year to 31 March 2025, it reported revenue of ₹18.12bn and net income of ₹1.18bn. At that date it held total assets of ₹17.78bn and shareholders' equity of ₹11.56bn.
Morepen Laboratories Ltd. engages in the manufacture and market of bulk drugs and pharmaceutical formulations. The company is headquartered in Gurgaon, Haryana. The firm is engaged in the business of manufacturing, producing, developing, and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also the home health products. Its APIs include Apixaban, Edoxaban, Sitagliptin, Linagliptin, Empagliflozin, Atorvastatin, Loratadine, Desloratadine, Montelukast Sodium, Atorvastatin Calcium, Fexofenadine, Sitagliptin Phosphate, Vildagliptin and Rivaroxaban, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier with HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 16 Nov 1992
- Employees
- 1,649
- Website
- morepen.com ↗
Leadership
Pay as last reported
- Mr. Sushil SuriExecutive Chairman of the Board, Managing Director₹90.8m
- Mr. Ajay SharmaChief Financial Officer
- Mr. Vipul SrivatavaCompliance Officer, Company Secretary
- Mr. Sanjay SuriWhole-Time Director, since 2019₹64.4m
- Mr. Sharad JainIndependent Director
- Mr. Ranjit KhattarIndependent Director
- Dr. Savita ..Non-Executive Independent Director₹175,000
- Mr. Praveen DuttNon-Executive Independent Director₹215,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Morepen Laboratories Ltd manufactures APIs like Apixaban and Edoxaban for global markets.
- The company produces branded formulations including Intebact Capsules and Intelicaps Lax for domestic consumption.
- Morepen Devices Limited develops home health products such as Dr. Morepen VP06 Vaporizer and Dr. Morepen CN06 Nebulizer.
Weaknesses
- Morepen Laboratories Ltd has 1,649 employees which is below industry average for large pharmaceutical firms.
- The company's focus on APIs like Sitagliptin may limit diversification in product portfolio.
- Morepen's home health products are limited to four items including Dr. Morepen ST06 Stethoscope.
Opportunities
- Morepen can expand API production to include Rivaroxaban and Empagliflozin for emerging markets.
- The company can leverage its subsidiary Dr. Morepen Limited to enter new geographic segments.
- Morepen's branded formulations like Rythmix Kid Syrup can target growing pediatric healthcare demand.
Threats
- Morepen's reliance on APIs like Atorvastatin Calcium faces increasing regulatory scrutiny in India.
- The pharmaceutical sector in India faces competition from multinational firms like Sun Pharma.
- Morepen's home health products face market saturation in the domestic health care segment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.